bpc-157 safety concerns fda warning This is the first vote from the FDA's Pharmacy Compounding Advisory Committee on one of 7 peptides up for consideration. While the committee advises through these votes, ultimately the will make FDA Panel Finds a Peptide

In a Phase 2 trial, the highest doses produced an average ~24% body-weight reduction at 11 months (American Diabetes Association)

Warning Letters issued to 503B Outsourcing Facilities were for cGMP violations, failure to submit Adverse Drug Reaction (ADR) reports to FDA (which 503B facilities are required to report), compounding unapproved drug products

Batch-specific Certificates of Analysis (COAs) are available to verify purity and identity

Instead of suppressing inflammation, they promote repair

BPC-157 Apex Biopharma , , BPC-157 (Body Protection Compound)

Learn more about the intersection of peptides and NAD+ and how they may work together to support cellular health and energy metabolism